1. Home
  2. Analysis
  3. Biktarvy
  4. Delstrigo

Biktarvy and Delstrigo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) and Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate). Common drug interactions include weight increased among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Biktarvy and Delstrigo. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Biktarvy?

Biktarvy has active ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 19,543 Biktarvy users. Check the latest studies of Biktarvy.

What is Delstrigo?

Delstrigo has active ingredients of doravirine; lamivudine; tenofovir disoproxil fumarate. eHealthMe is studying from 212 Delstrigo users. Check the latest studies of Delstrigo.

On Jul, 12, 2026

35 people who take Biktarvy and Delstrigo together, and have interactions are studied.

Biktarvy and Delstrigo drug interactions.

What are the common drug interactions of Biktarvy and Delstrigo, by gender? *:

female:

  1. Weight increased
  2. Arthralgia (joint pain)
  3. Eating disorder
  4. Psychiatric symptom
  5. Back pain
  6. Hyperphagia (an abnormal appetite for food)
  7. Stress
  8. Blood glucose increased
  9. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  10. Anhedonia (inability to experience pleasure from activities usually found enjoyable)

male:

  1. Death
  2. Pain
  3. Bone density decreased
  4. Chest pain
  5. Chronic kidney disease
  6. Cough
  7. Diarrhoea
  8. Drug hypersensitivity
  9. Drug ineffective
  10. Drug intolerance (drug sensitivity)

What are the common drug interactions of Biktarvy and Delstrigo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Arthralgia (joint pain)
  2. Eating disorder
  3. Weight increased
  4. Psychiatric symptom
  5. Back pain
  6. Hyperphagia (an abnormal appetite for food)
  7. Stress

30-39:

  1. Anxiety disorder
  2. Dyspnoea (difficult or laboured respiration)
  3. Nightmare (unpleasant dream)
  4. Pancreatitis acute (sudden inflammation of pancreas)
  5. Panic attack

40-49:

  1. Diarrhoea
  2. Drug hypersensitivity
  3. Drug ineffective
  4. Drug intolerance (drug sensitivity)
  5. Dyspnoea (difficult or laboured respiration)
  6. Genotype drug resistance test positive
  7. Heart rate increased
  8. Ill-defined disorder
  9. Muscle spasms (muscle contraction)
  10. Oropharyngeal pain

50-59:

  1. Back pain
  2. Depression
  3. Weight increased

60+:

  1. Death

* Approximation only. Some reports may have incomplete information.

Do you take Biktarvy and Delstrigo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Biktarvy and Delstrigo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Delstrigo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Biktarvy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Delstrigo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate and doravirine; lamivudine; tenofovir disoproxil fumarate (the active ingredients of Biktarvy and Delstrigo, respectively), and Biktarvy and Delstrigo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.